Introduction
Lung cancer is the leading cause of cancer-related death in both men and women in the United States. 1 Non-small cell lung cancer (NSCLC) makes up 83% of lung cancer cases, 2 and it has a 5-year overall survival (OS) rate of 21% when considering all stages together. 1 Surgery remains the first-line treatment for the majority of patients with stage I or II NSCLC, and most patients with stage III or IV NSCLC will typically receive chemotherapy with or without radiotherapy.
2 Therefore, great effort has been placed on investigating perioperative factors that could predict and/or improve the poor survival rates of this patient population. 3, 4 Current risk-stratification characteristics used in patients with NSCLC are associated with surgical staging and include tumor size, invasion to adjacent organs, nodal status, and presence of metastasis. Some clinically available inflammatory biomarkers have been identified to improve and guide therapy in patients with cancer, particularly those with NSCLC. 5 We previously reported the importance of the preoperative neutrophil-to-lymphocyte ratio in the context of NSCLC, indicating that those with a high preoperative inflammatory status have an elevated mortality risk; however, other investigated markers, including the platelet-to-lymphocyte ratio, have been shown to correlate with poor prognosis in various types of cancer. [6] [7] [8] [9] The interaction between platelets and cancer cells, as well as between platelets and immune cells, has previously been described, and platelets may mediate tumor growth by stimulating angiogenesis and inducing immunosuppression through the release of growth factors. 10, 11 The potential link between inflammation and cancer has been previously studied, and findings suggest that an inflammatory microenvironment promotes tumor growth, progression, and immunosuppression.
12, 13 Understanding cancer-associated inflammation is crucial because this information can be used to predict survival in most patient with cancer, including those with NSCLC. 5 Similarly, use of nonsteroidal antiinflammatory drugs (NSAIDs) has been implicated in the modulation of cancer-related inflammation; moreover, use of NSAIDs could reduce proliferation, invasion, and micrometastasis of malignant cells by reducing the inflammatory state associated with the tumor microenvironment and by promoting apoptosis in cancer cells. [14] [15] [16] In the context of oncological surgery, a retrospective study demonstrated an association between intraoperative use of NSAIDs and improved oncological outcomes in breast cancer; this finding may be the result of a reduction in the inflammatory response associated with surgery. 5, 17 The predictive value of the platelet-to-lymphocyte ratio has not been determined in patients with NSCLC. Therefore, the aim of this retrospective study is to test the hypothesis that a low perioperative platelet-to-lymphocyte ratio is associated with improved recurrencefree survival (RFS) and OS rates in patients with NSCLC undergoing surgery. We also investigated the effects of NSAID use on survival rates in patients with high and low platelet-to-lymphocyte ratios.
Methods

Patient Selection
This study was approved by the Institutional Review Board of the University of Texas MD Anderson Cancer Center (Houston, TX). Demographical, perioperative, and survival data were retrieved from the MD Anderson Research Electronic Data Capture database for patients with NSCLC. We obtained information for 1,637 patients with stage I, II, or III NSCLC who underwent surgery between January 1, 2004, and July 31, 2011. Patients 18 years of age or older who underwent thoracic surgery for NSCLC with intention to cure were included in the analysis. We excluded those who had undergone palliative surgery or had secondary malignancies.
All patients had surgery under balanced, general anesthesia. Postoperative pain management consisted of patient-controlled epidural analgesia or patient-controlled intravenous opioid analgesia with or without the addition of NSAIDs that started within 72 hours after surgery. Those patients treated with NSAIDs received ketorolac (30-60 mg/day), ibuprofen (200-800 mg/day), rofecoxib (50 mg/day), or celecoxib (200-300 mg/day) alone or in combination.
Statistical Analysis
The following variables were included in our analysis: age, sex, body mass index, American Society of Anesthesiologists (ASA) physical status, tumor histology, stage of disease, type of surgery, types and doses of NSAIDs, and neoadjuvant chemotherapy with or without adjuvant chemotherapy with or without radiotherapy.
The platelet-to-lymphocyte ratio was calculated as the platelet count divided by the lymphocyte count. Preoperative platelet-to-lymphocyte ratios and postoperative platelet-to-lymphocyte ratios on days 1, 2, and 3 were calculated from routine complete blood counts. The primary end points of this study were RFS and OS. RFS was defined as the time in months from the date of surgery to the date of recurrence or the date of death, whichever occurred first. 5 Patients were censored at the last recurrence-free date if neither recurrence nor death occurred. OS was defined as the time in months from surgery to death from any cause. 5 Descriptive statistics for demographics and baseline patient characteristics, including mean, standard deviation, median, and interquartile range, were calculated for continuous variables. Frequency counts and percentages were calculated for categorical variables. A Fisher exact test or chi-square test was used to evaluate the association between 2 categorical variables. A Kruskal-Wallis test was used to evaluate the difference in a continuous variable between patient groups. Two different cutoff values were used to discriminate patients with high inflammatory status from those with low status. First, the median platelet-to-lymphocyte ratio at each time point (preoperative and postoperative days 1, 2, and 3) was used to divide patients with high inflammatory status from those with low status. We also used a cutoff value of 180 to discriminate between patients with high preoperative and postoperative platelet-to-lymphocyte ratios (≥ 180) from those with low ratios (< 180). 18 The Kaplan-Meier method was used for time-to-event analysis, including RFS and OS analyses. The median time to event in months and survival rates at 3 and 5 years with 95% confidence intervals (CIs) were calculated. The log-rank test was used to evaluate the differences in time-to-event end points between patient groups. Univariate Cox proportional hazard ratio (HR) models were fitted to evaluate the effects of continuous variables on RFS and OS. Multivariable Cox proportional HR models were used for multivariate analyses to include covariates associated with prognosis in previous studies or had a P value of less than .2 in univariate analyses. 5, 19 A P value less than .05 was considered statistically significant. SAS 9.1.3 (SAS, Cary, NC) and S-Plus 8.0 (TIBCO Software, Palo Alto, CA) were used for the analyses. ASA = American Society of Anesthesiologists, BMI = body mass index, IQD = interquartile deviation, SD = standard deviation.
Results
Patient Characteristics
patients who had adenocarcinoma with the percentage of those with other forms of NSCLC within each disease stage, the percentages were higher among those with stage I disease (58.5%) and among those with stage III disease (56.5%) than among those with stage II disease (46.8%). Thoracotomy was the most common surgical procedure across the 3 groups of patients, although more than one-third (35.8%) of patients with stage I disease underwent video-assisted thoracoscopic surgery (see Table 1 ). Most patients with stage I or II tumors did not receive neoadjuvant or adjuvant chemotherapy or radiotherapy; by contrast, patients with stage III disease were more likely to receive adjuvant chemotherapy (38.9%) or radiotherapy (39.9%; see Table 1 ). A statistically significant difference was found in the median preoperative platelet-to-lymphocyte ratio values among patients with various tumor stages. Patients with stage I disease had the lowest preoperative platelet-to-lymphocyte ratios compared with those with stage II/III disease (P < .0001; see Table 1 ). Similarly, when the analysis was conducted using the median values of the entire population or a cutoff platelet-to-lymphocyte ratio of 180, a larger percentage of patients in stage I had lower platelet-to-lymphocyte ratios than these cutoff values (P = .0001 for both cutoff levels). Despite an increase in postoperative platelet-tolymphocyte ratios across all groups, the statistical analysis demonstrated that patients' median values on days 1 and 2 significantly differed among the various tumor stages. As shown in Table 1 , patients with stage III tumors had the highest postoperative median platelet-tolymphocyte ratios. When we analyzed the proportion of patients with platelet-to-lymphocyte ratios greater than or less than the median or those that were higher or lower than 180, no statistically significant differences were observed, except on postoperative day 2. Patients with a platelet-to-lymphocyte ratio of at least 180 on postoperative day 2 had a higher tumor stage (stage I = 35.7% vs stage II = 46.8% vs stage III = 48.1%; P = .009). A similar trend was found when the median was considered as the cutoff value (P = .082).
In regard to the perioperative use of NSAIDs, 931 patients (56.87%) received this type of analgesic; 771 (47.1%) were treated with ketorolac alone or in combination with ibuprofen, celecoxib, or both. A statistically significant difference was found between use and nonuse of ketorolac among the various tumor stages. Ketorolac was more commonly administered to patients with higher tumor stages than to those with stage I disease (P = .006; see Table 1 
Recurrence-Free Survival
The median RFS rate of the overall population was 76 months (95% confidence interval [CI], 68.33-88.53), and the RFS rates at 3 and 5 years were 64% (95% CI, 62-66) and 55% (95% CI, 53-58), respectively. The univariate analysis showed that age, male sex, ASA physical status 3/4, neoadjuvant chemotherapy, adjuvant radiotherapy, and open thoracotomy were all associated with decreased rates of RFS at 3 and 5 years ( Table 2 ). The analysis also demonstrated that patients with stage I disease had the highest RFS rates at 3 and 5 years (76% and 68%, respectively) compared with patients with stage II (58% and 46%, respectively) or III disease (44% and 38%, respectively; P < .0001). The univariate analysis also demonstrated that a preoperative platelet-to-lymphocyte ratio greater than the median (133) or higher than 180 was a predictor of poor RFS rate (P = .0002; see Table 2 ). Similarly, a platelet-to-lymphocyte ratio above 180 but not greater than the median value on postoperative day 3 was associated with significant changes in RFS (P = .0414), but not postoperative day 1 (P = .3937) or 2 (P = .2206; Fig 1) . Use of NSAIDs perioperatively was not associated with longer rates of RFS (P = .719).
In a multivariate model analysis, a high preoperative platelet-to-lymphocyte ratio (≥ 180), older age, and male sex were associated with 22% (P = .019), 2% (P < .0001), and 19% (P = .021) increases the risk of recurrence, respectively (Table 3) . Tumor staging was also an independent prognostic factor of poor RFS. Thus, patients with stage II/III disease had an increased recurrence risk of 77% (P < .0001) and 116% (P < .0001), respectively, compared with the risk for patients with stage I disease. Other variables associated with shorter rates of RFS were administration of neoadjuvant chemotherapy (HR = 1.339; 95% CI, 1.107-1.621; P = .0026) and adjuvant radiotherapy (HR = 1.340; 95% CI = 1.083-1.657; P = .0070). The single factor that was significantly associated with longer rates of survival was minimally invasive surgery; patients who underwent this surgery had a 19% reduced risk of recurrence (P = .049; see Table 3 ).
Because the preoperative and postoperative platelet-to-lymphocyte ratios of patients treated with ketorolac were statistically different, we investigated the association between platelet-to-lymphocyte ratios and RFS rates in these 2 populations of patients.
The log-rank analysis demonstrated that a preopera-tive (P =
: P = .104; postoperative day 2: P = .952; and postoperative day 3: P = .307) in patients taking ketorolac. By contrast, a platelet-to-lymphocyte ratio higher than 180 was associated with poor survival in patients not treated with ketorolac (preoperative: P = .0006; postoperative day 1: P = .272; postoperative day 2: P = .008; and postoperative day 3: P = .014).
Overall Survival
platelet-to-lymphocyte ratio (≥ 180), older age, male, ASA physical status 3/4, ASA physical status 2/3, use of neoadjuvant chemotherapy, use of adjuvant radiotherapy, and thoracotomy were associated with a decreased OS rate (Table 4; Fig 2) . The OS rates at 3 and 5 years were not statistically significant different between patients who did or did not receive perioperative NSAIDs (P = .443), or between those with a ratio higher than or less than 180, and a median higher or lower platelet-to-lymphocyte ratio on postoperative continued on next page days 1 (P = .907), 2 (P = .103), and 3 (P = .066). The multivariate analysis showed that age (HR = 1.034; 95% CI, 1.024-1.044; P < .0001), male sex (HR = 1.328; 95% CI, 1.109-1.590; P = .002), postoperative radiotherapy (HR = 1.337; 95% CI, 1.052-1.698; P = .0176), and higher tumor stage (II vs I: HR = 1.864, 95% CI, 1.488-2.335, P < .0001; III vs I: HR = 2.451, 95% CI, 1.922-3.125, P < .0001) were independent predictor factors of poor OS ( Table 5 ). The analysis also demonstrated that a preoperative platelet-to-lymphocyte ratio of at least 180 was associated with a 33% increase in mortality after surgery (P = .0036).
We also investigated the association between platelet-to-lymphocyte ratios and OS in patients treated with or without ketorolac. Similar to the findings in RFS, preoperative (P = .197) and postoperative (day 1: P = .302; day 2: P = .678; and day 3: P = .653) platelet-to-lymphocyte ratios higher than or less than 180 were not associated with a change in survival among patients treated with ketorolac. However, a platelet-tolymphocyte ratio higher than 180 was associated with poor survival in patients not treated with ketorolac (preoperative: P = .0002; postoperative day 1: P = .278; postoperative day 2: P = .013; and postoperative day 3: P = .039).
Discussion
The platelet-to-lymphocyte ratio has emerged as a potential inflammatory biomarker and a predictor of toxicity-and cancer-related survival and OS rates in pa- [20] [21] [22] Similar to the results of previously published studies, our work shows that the preoperative platelet-to-lymphocyte ratio -but not the early postoperative platelet-to-lymphocyte ratio -is a predictor of recurrence and mortality in patients with NSCLC undergoing surgery.
Three other studies failed to demonstrate the prognostic value of the platelet-to-lymphocyte ratio; however, several differences can be seen between those studies and the present study. 20, 23, 24 The sample size in the other studies was significantly smaller than that in the present work; therefore, these previous reports might have been statistically underpowered to detect a difference in survival between patients with a high or low inflammatory status. 20, 23, 24 By contrast, to the best of our knowledge, the sample size of the present study is the largest of all studies that have addressed the prognostic value of platelet-to-lymphocyte ratios in patients with NSCLC. The studied population of patients in the previously published 3 reports was different from ours. Preoperative platelet-tolymphocyte ratio (≥ 180 vs < 180) included elderly patients with stage I disease, and Unal et al 20 had a larger proportion of patients with squamous cell histology. Our study included patients who were younger, and adenocarcinoma was the most common histology. Although the cutoff values (determined as the median platelet-to-lymphocyte or platelet-to-lymphocyte ratio = 180) used in our study were arbitrary, they were different from those used in the other prior reports. 20, 23, 24 The findings of this study highlight the importance of inflammatory status on the survival of patients with NSCLC. Inflammation is involved in many aspects of malignancy, including tumor escape, cell survival and proliferation, epithelial-mesenchymal transformation, and metastasis. 25, 26 Activation of platelets in the context of inflammation can favor tumor progression by several mechanisms, including immunosuppression and angiogenesis. It has even been suggested that platelets can "cover" cancer cells, resulting in the escape of cancer cells from immune cytotoxic cells such as natural killer cells. 27 Platelets can also release growth factors, such as prostaglandin E, vascular endothelial growth factor, and transforming growth factor that disrupt the function of natural killer cells and stimulate the growth of cancer cells. 27, 28 Absolute or relative lymphopenia is another important component of a high platelet-to-lymphocyte ratio in patients with NSCLC. The results from a previous study indicated that patients with low lymphocyte nadirs undergoing radiotherapy have lower rates of survival than patients whose lymphocyte levels are higher. 29 Likewise, Campian et al 30 observed an association between severe lymphopenia and reduced survival in patients with NSCLC. The results of these publications are in agreement with a recent study demonstrating that patients with NSCLC who have a high inflammatory status and a number of low CD8-positive T cells at the tumor level have a higher risk of mortality. 31 Our study also showed that patients with more advanced disease had a higher platelet-to-lymphocyte ratio, suggesting a link between the amount of tumor burden and the magnitude of systemic inflammatory response. This finding is in agreement with previous studies, including a smaller cohort of patients, indicating an association between stage of disease and systemic inflammation. 5, 32 For example, patients with gynecological, breast, or colorectal cancer who have elevated platelet-to-lymphocyte ratios have a higher risk of positive lymph nodes and larger tumors than those whose ratios are lower. [32] [33] [34] [35] In terms of the postoperative inflammatory response, our analysis demonstrated that patients with stage II/III disease had significantly higher platelet-tolymphocyte ratios than did patients with stage I disease. This phenomenon might be related to the magnitude of the surgical insult because a larger proportion of patients with stage II/III disease underwent thoracotomies than thoracoscopies. These findings are supported by Whitson et al, 36 who showed that markers of inflammatory response such as interleukin 6 correlate with the magnitude of surgical trauma. Although we failed to demonstrate an association between high postoperative platelet-to-lymphocyte ratios and poor rates of survival, it is possible that using higher cutoff values than those chosen for this study may have resulted in better predictive ability.
Limitations
Our study has the inherent limitations of any retrospective study; therefore, the results must be interpreted with caution. Missing and/or confounding variables not included in the statistical analysis could have influenced the survival findings of the studied popula- Preoperative platelet-to-lymphocyte ratio (≥ 180 vs < 180)
1.334 (1.099-1.620) .0036 ASA = American Society of Anesthesiologists, BMI = body mass index, CI = confidence interval, HR = hazard ratio. tion of patients. For example, we did not account for the presence of mutations, for the type of biologically targeted therapeutic agents, or for conventional chemotherapy given postoperatively. We used 2 different cutoff values to assess the impact of the platelet-to-lymphocyte ratio on rates of RFS and OS. The chosen values were arbitrarily determined, so they are not based on a receiving operative-curve analysis. The plateletto-lymphocyte ratio calculation was based on the absolute lymphocyte count obtained from the complete blood cell count; hence, the statistical analysis did not account for subpopulations of lymphocytic cells. Use of NSAIDs after surgery might have been influenced by factors such as intraoperative bleeding and comorbidities that might be considered sources of bias. Our analysis also did not include variables such as intraoperative vs postoperative use of NSAIDs, class of NSAID, or the total amount of each analgesic. Therefore, we cannot comment on whether the class of NSAID, time, and amount of administration of each NSAID might have had an impact on the survival of our population of patients.
Conclusions
Our results show that a high preoperative inflammatory status is an independent predictor of recurrence-free and overall survival rates in patients with non-small-cell lung cancer. The preoperative plateletto-lymphocyte ratio is a simple and readily available laboratory parameter that can be used as an independent prognostic factor of recurrence-free survival and overall survival in patients with nonmetastatic, operable non-small-cell lung cancer. Further research is needed to determine the association between a high platelet-to-lymphocyte ratio and type of recurrence (local vs distant). Other independent factors of survival include age, male sex, tumor stage, and type of surgery.
